Firefly Neuroscience, Inc.(AIFF)Earnings, Financials & Key Ratios
AIFF•NASDAQ
$2.06
$29M mkt cap·Price updated May 6, 2026
AboutFirefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.Show more
- Revenue$108K-78.3%
- EBITDA-$9M-252.7%
- Net Income-$10M-301.8%
- EPS (Diluted)-1.60-384.8%
- Gross Margin37.96%-62.0%
- EBITDA Margin-8437.96%-1526.2%
- Operating Margin-8500%-1275.2%
- Net Margin-9685.19%-1752.9%
- Interest Coverage-133.04+22.2%
AIFF Key Insights
Firefly Neuroscience, Inc. (AIFF) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓Share count reduced 16.8% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AIFF Price & Volume
Firefly Neuroscience, Inc. (AIFF) stock price & volume — 10-year historical chart
Loading chart...
AIFF Growth Metrics
Firefly Neuroscience, Inc. (AIFF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years50%
TTM-60.21%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-208.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-185.84%
Return on Capital
10 Years-1401.48%
5 Years-1401.48%
3 Years-2823.85%
Last Year-
AIFF Peer Comparison
Firefly Neuroscience, Inc. (AIFF) competitors in Vertical industry SaaS applications — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MBRX | 29.5M | 2.49 | -0.09 | -319.85% | 0.01 | |||
 NRXP | 84.15M | 3.04 | -2.27 | -157.28% | ||||
 BTAI | 3.17M | 1.25 | -0.05 | 64.2% | -90.71% | |||
 NVAX | 1.34B | 8.11 | 3.14 | 64.69% | 39.19% | |||
 AXSM | 11.41B | 223.06 | -60.61 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.69B | 22.65 | 6.86 | 18.52% | 65.38% | 23.12% | 11.58% | |
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 |
Compare AIFF vs Peers
Firefly Neuroscience, Inc. (AIFF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AIFF Income Statement
Firefly Neuroscience, Inc. (AIFF) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 13.9M | 32K | 0 | 498K | 108K | 783K |
| Revenue Growth % | - | -99.77% | -100% | - | -78.31% | -60.21% |
| Cost of Goods Sold | 11.69M | 0 | 0 | 0 | 67K | 267K |
| COGS % of Revenue | 84.11% | - | - | - | 62.04% | - |
| Gross Profit | 2.21M▲ 0% | 32K▼ 98.6% | 0▼ 100.0% | 498K▲ 0% | 41K▼ 91.8% | 516K▲ 0% |
| Gross Margin % | 15.89% | 100% | - | 100% | 37.96% | 65.9% |
| Gross Profit Growth % | - | -98.55% | -100% | - | -91.77% | - |
| Operating Expenses | 1.8M | 4.69M | 3.33M | 3.58M | 9.22M | 10.31M |
| OpEx % of Revenue | 12.93% | 14643.75% | - | 718.07% | 8537.96% | - |
| Selling, General & Admin | 1.8M | 1.68M | 1.98M | 2.83M | 7.33M | 7.82M |
| SG&A % of Revenue | 12.93% | 5253.13% | - | 569.28% | 6790.74% | - |
| Research & Development | 0 | 2.93M | 1.27M | 741K | 1.95M | 1.46M |
| R&D % of Revenue | - | 9143.75% | - | 148.8% | 1809.26% | - |
| Other Operating Expenses | 0 | 79K | 77K | 0 | -67K | 1.03M |
| Operating Income | 411.85K▲ 0% | -4.65M▼ 1230.0% | -3.33M▲ 28.5% | -3.08M▲ 7.5% | -9.18M▼ 198.2% | -9.79M▲ 0% |
| Operating Margin % | 2.96% | -14543.75% | - | -618.07% | -8500% | -1250.45% |
| Operating Income Growth % | - | -1230.03% | 28.47% | 7.54% | -198.25% | - |
| EBITDA | 423.91K | -4.22M | -3.31M | -2.58M | -9.11M | -9.62M |
| EBITDA Margin % | 3.05% | -13203.13% | - | -518.88% | -8437.96% | -1229.12% |
| EBITDA Growth % | - | -1096.67% | 21.54% | 22.05% | -252.67% | -41.64% |
| D&A (Non-Cash Add-back) | 12.06K | 429K | 14K | 0 | 67K | 167K |
| EBIT | 413.38K | -4.25M | -3.21M | -2.58M | -10.39M | -19.68M |
| Net Interest Income | 0 | -135K | -574K | -18K | -69K | -127K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 59K |
| Interest Expense | 0 | 135K | 574K | 18K | 69K | 186K |
| Other Income/Expense | 1.53K | 273K | -460K | 476K | -1.28M | -11.39M |
| Pretax Income | 413.38K▲ 0% | -4.38M▼ 1159.8% | -3.79M▲ 13.5% | -2.6M▲ 31.3% | -10.46M▼ 301.9% | -21.18M▲ 0% |
| Pretax Margin % | 2.97% | -13690.63% | - | -522.49% | -9683.33% | -2705.11% |
| Income Tax | 0 | 0 | 0 | 1K | 2K | 6K |
| Effective Tax Rate % | 0% | 0% | 0% | -0.04% | -0.02% | -0.03% |
| Net Income | 413.38K▲ 0% | -4.38M▼ 1159.8% | -3.79M▲ 13.5% | -2.6M▲ 31.3% | -10.46M▼ 301.8% | -21.19M▲ 0% |
| Net Margin % | 2.97% | -13690.63% | - | -522.69% | -9685.19% | -2705.87% |
| Net Income Growth % | - | -1159.8% | 13.51% | 31.3% | -301.84% | -208.05% |
| Net Income (Continuing) | 413.38K | -4.38M | -3.79M | -2.6M | -10.46M | -21.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.05▲ 0% | -0.56▼ 1166.7% | -0.48▲ 14.3% | -0.33▲ 31.2% | -1.60▼ 384.8% | -1.57▲ 0% |
| EPS Growth % | - | -1166.67% | 14.29% | 31.25% | -384.85% | -185.84% |
| EPS (Basic) | 0.05 | -0.56 | -0.48 | -0.33 | -1.60 | - |
| Diluted Shares Outstanding | 7.87M | 7.87M | 7.87M | 7.87M | 6.55M | 13.5M |
| Basic Shares Outstanding | 7.87M | 7.87M | 7.87M | 7.87M | 6.55M | 13.2M |
| Dividend Payout Ratio | - | - | - | - | - | - |
AIFF Balance Sheet
Firefly Neuroscience, Inc. (AIFF) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 3.35M | 703K | 83K | 2.25M | 2.63M | 5.43M |
| Cash & Short-Term Investments | 1.86M | 653K | 58K | 2.14M | 1.81M | 4.33M |
| Cash Only | 1.86M | 653K | 58K | 2.14M | 1.81M | 4.33M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.44M | 41K | 19K | 84K | 121K | 0 |
| Days Sales Outstanding | 37.86 | 467.66 | - | 61.57 | 408.94 | 48.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 80K |
| Days Inventory Outstanding | - | - | - | - | - | 72.79 |
| Other Current Assets | 27.63K | 0 | 0 | 0 | 280K | 184K |
| Total Non-Current Assets | 419.61K | 250K | 52K | 386K | 1.97M | 6.98M |
| Property, Plant & Equipment | 113.57K | 188K | 0 | 0 | 136K | 235K |
| Fixed Asset Turnover | 122.42x | 0.17x | - | - | 0.79x | 4.89x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 5.17M |
| Intangible Assets | 0 | 1K | 0 | 386K | 180K | 898K |
| Long-Term Investments | 210.69K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 95.35K | 61K | 52K | 0 | 1.66M | 5.01M |
| Total Assets | 3.77M▲ 0% | 953K▼ 74.7% | 135K▼ 85.8% | 2.64M▲ 1856.3% | 4.6M▲ 74.2% | 12.41M▲ 0% |
| Asset Turnover | 3.68x | 0.03x | - | 0.19x | 0.02x | 0.07x |
| Asset Growth % | - | -74.75% | -85.83% | 1856.3% | 74.21% | 787.53% |
| Total Current Liabilities | 1.8M | 3.97M | 2.25M | 2.53M | 4.98M | 2.72M |
| Accounts Payable | 103.65K | 500K | 420K | 630K | 1.82M | 1.34M |
| Days Payables Outstanding | 3.24 | - | - | - | 9.89K | 2.14K |
| Short-Term Debt | 138.6K | 1.79M | 0 | 0 | 694K | 0 |
| Deferred Revenue (Current) | 946.88K | 459K | 909K | 0 | 13K | 296K |
| Other Current Liabilities | 57.4K | 0 | 0 | 0 | 827K | 716K |
| Current Ratio | 1.86x | 0.18x | 0.04x | 0.89x | 0.53x | 0.53x |
| Quick Ratio | 1.86x | 0.18x | 0.04x | 0.89x | 0.53x | 0.53x |
| Cash Conversion Cycle | - | - | - | - | - | -2.02K |
| Total Non-Current Liabilities | 356.99K | 0 | 0 | 0 | 0 | 31K |
| Long-Term Debt | 356.99K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 31K |
| Total Liabilities | 2.16M | 3.97M | 2.25M | 2.53M | 4.98M | 2.75M |
| Total Debt | 495.6K | 1.79M | 0 | 0 | 694K | 0 |
| Net Debt | -1.36M | 1.14M | -58K | -2.14M | -1.12M | -4.33M |
| Debt / Equity | 0.31x | - | - | - | - | 0.00x |
| Debt / EBITDA | 1.17x | - | - | - | - | -0.00x |
| Net Debt / EBITDA | -3.21x | - | - | - | - | 0.45x |
| Interest Coverage | - | -34.47x | -5.80x | -171.00x | -133.04x | -105.82x |
| Total Equity | 1.61M▲ 0% | -3.01M▼ 286.8% | -2.11M▲ 30.0% | 109K▲ 105.2% | -375K▼ 444.0% | 9.66M▲ 0% |
| Equity Growth % | - | -286.81% | 29.96% | 105.16% | -444.04% | 784.74% |
| Book Value per Share | 0.20 | -0.38 | -0.27 | 0.01 | -0.06 | 0.72 |
| Total Shareholders' Equity | 1.61M | -3.01M | -2.11M | 109K | -375K | 9.66M |
| Common Stock | 129.04K | 0 | 19K | 0 | 0 | 1K |
| Retained Earnings | -12.31M | -67.33M | -73.91M | -76.62M | -87.08M | -108.9M |
| Treasury Stock | -930.21K | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
AIFF Cash Flow Statement
Firefly Neuroscience, Inc. (AIFF) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | 423.26K | -3.82M | -2.89M | -2.17M | -6.16M | -6.16M |
| Operating CF Margin % | 3.04% | -11937.5% | - | -436.14% | -5699.07% | - |
| Operating CF Growth % | - | -1002.51% | 24.29% | 24.9% | -183.38% | -305.74% |
| Net Income | 413.38K | -4.38M | -3.79M | -2.6M | -10.46M | -21.19M |
| Depreciation & Amortization | 12.06K | 429K | 14K | 0 | 67K | 179K |
| Stock-Based Compensation | 0 | 608K | 60K | 295K | 2.72M | 403K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 27.63K | -283K | 432K | 0 | 1.07M | 12.92M |
| Working Capital Changes | -29.8K | -193K | 391K | 136K | 445K | 75K |
| Change in Receivables | -984.21K | 26K | 27K | -65K | -37K | 71K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 28K |
| Change in Payables | -112.58K | 206K | -80K | 35K | 883K | -166K |
| Cash from Investing | -64.55K | 1.6M | 262K | -386K | -477K | -2.54M |
| Capital Expenditures | -64.55K | 0 | 0 | -386K | -148K | -185K |
| CapEx % of Revenue | 0.46% | - | - | 77.51% | 137.04% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -2.36M |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 597K | 262K | 0 | -329K | 4K |
| Cash from Financing | 460K | 2.04M | 2.04M | 4.64M | 6.3M | 13.24M |
| Debt Issued (Net) | 450K | 2.04M | 1.75M | 0 | 1.96M | 1.96M |
| Equity Issued (Net) | 10K | 0 | 290K | 1000K | 1000K | 1.9M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -19K |
| Other Financing | 0 | 0 | 0 | 0 | 36K | 8.83M |
| Net Change in Cash | 818.72K▲ 0% | -181K▼ 122.1% | -595K▼ 228.7% | 2.08M▲ 450.4% | -333K▼ 116.0% | 3.1M▲ 0% |
| Free Cash Flow | 358.72K▲ 0% | -3.82M▼ 1164.9% | -2.89M▲ 24.3% | -2.56M▲ 11.5% | -6.57M▼ 156.8% | -7.79M▲ 0% |
| FCF Margin % | 2.58% | -11937.5% | - | -513.65% | -6083.33% | -995.15% |
| FCF Growth % | - | -1164.9% | 24.29% | 11.55% | -156.84% | -31.55% |
| FCF per Share | 0.05 | -0.49 | -0.37 | -0.33 | -1.00 | -1.00 |
| FCF Conversion (FCF/Net Income) | 1.02x | 0.87x | 0.76x | 0.83x | 0.59x | 0.37x |
| Interest Paid | 0 | 0 | 0 | 0 | 11K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
AIFF Key Ratios
Firefly Neuroscience, Inc. (AIFF) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -2388.07% | - | -219.4% |
| Return on Invested Capital (ROIC) | - | - | - | - | -518.68% |
| Gross Margin | 100% | - | 100% | 37.96% | 65.9% |
| Net Margin | -13690.63% | - | -522.69% | -9685.19% | -2705.87% |
| Debt / Equity | - | - | - | - | 0.00x |
| Interest Coverage | -34.47x | -5.80x | -171.00x | -133.04x | -105.82x |
| FCF Conversion | 0.87x | 0.76x | 0.83x | 0.59x | 0.37x |
| Revenue Growth | -99.77% | -100% | - | -78.31% | -60.21% |
AIFF Frequently Asked Questions
Firefly Neuroscience, Inc. (AIFF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Firefly Neuroscience, Inc. (AIFF) reported $0.8M in revenue for fiscal year 2024. This represents a 94% decrease from $13.9M in 2020.
Firefly Neuroscience, Inc. (AIFF) saw revenue decline by 78.3% over the past year.
Firefly Neuroscience, Inc. (AIFF) reported a net loss of $21.2M for fiscal year 2024.
Dividend & Returns
Firefly Neuroscience, Inc. (AIFF) had negative free cash flow of $7.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More AIFF
Firefly Neuroscience, Inc. (AIFF) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates